close

Agreements

1 210 211 212 213 214 228
Number of results: 4541

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-11-08 ADx NeuroSciences (Belgium) KU Leuven (Belgium) antibodies used in dementia diagnosis

development
licensing

 

 

Neurodegenerative diseases Development agreement
2011-11-07 Antitope (UK) Therapure Biopharma (Canada) therapeutic monoclonal antibodies

R&D

R&D agreement
2011-11-07 Oxford Gene Technology (UK) Abcodia (UK) pancreatic cancer specific biomarkers pancreatic cancer

development
collaboration

Cancer - Oncology Development agreement
2011-11-03 Ark Therapeutics (UK) University of Glasgow's Institute of Cardiovascular and Medical Sciences (UK) adenoviral vector expressing TIMP3 gene vein graft failure associated with coronary artery bypass surgery

manufacturing
production

Cardiovascular diseases Production agreement
2011-11-02 MorphoSys (Germany) Shionogi (Japan) HuCAL antibody technology and additional proprietary technology modules for research in drug discovery

R&D

licensing

R&D agreement
2011-11-02 Exonhit (France) Allergan (USA) new drugs for the treatment of neurodegenerative diseases, pain and ophthalmology

R&D

development

commercialisation

Neurodegenerative diseases - Ophtalmological diseases - CNS diseases R&D agreement
2011-11-02 Illumina (USA) Siemens Healthcare Diagnostics (USA), subsidiary of Siemens AG (Germany) next-generation sequencing for the rapid, accurate identification of patients\' infectious disease states and potential treatment paths.

development

Infectious diseases Development agreement
2011-11-02 BioQuanta (France) Gentronix (UK) Mitoxis® functional metabolomics platform

distribution
commercialisation

Commercialisation agreement
2011-11-01 GSK (UK) Alnylam Pharmaceuticals (USA - MA) VaxiRNA® technology

R&D
manufacturing
production

Infectious diseases R&D agreement
2011-10-31 Oxford BioMedica (UK) Mayo Clinic (USA) gene therapy using LentiVector® gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene

R&D

Ophtalmologic diseases R&D agreement
2011-10-30 Antitope (UK) Kolltan Pharmaceuticals (USA) therapeutic monoclonal antibodies for the treatment of cancer cancer

R&D

Cancer - Oncology R&D agreement
2011-10-28 Topotarget (Denmark) Multimeric Biotherapeutics (USA) multimeric TNF superfamily ligands (TNFSFs)

licensing

Licensing agreement
2011-10-28 Protagen (Germany) Charles River (USA) protein analytics from detailed protein characterization to stability and lot release testing

commercialisation

Commercialisation agreement
2011-10-28 Atlab Pharma (France) BZL Biologics (USA) 177Lu-J591

licensing

Cancer - Oncology Licensing agreement
2011-10-27 Oncodesign (France) Taconic (USA) pre-clinical oncology in vivo solutions for researchers

development
promotion

Cancer - Oncology Establishment of a new subsidiary in the EU
2011-10-26 Sanofi (France) Immune Design Corp (USA) Glucopyranosyl Lipid Adjuvant (GLA) technology allergy

R&D

Allergic diseases - Immunological diseases R&D agreement
2011-10-25 Lonza (Switzerland) Genmab (Denmark) HuMax-TF® \

development
manufacturing
production

 

Cancer Oncology Production agreement
2011-10-25 Probiogen (Germany) Inhibrx (USA) GlymaxX® Antibody Glyco-Engineering technology

licensing

Licensing agreement
2011-10-24 Encap Drug Delivery (UK) Lena Nanoceutics (UK) drug delivery technology (Nano-Capsules) combining nano-particle engineering technology with liquid filled hard capsule technology

development

Development agreement
2011-10-24 Silence Therapeutics (UK) Mirna Therapeutics (USA) novel microRNAs candidate drugs based on AtuPLEX™ and DBTC delivery systems undisclosed

R&D
collaboration

R&D agreement